Goodwin Procter recently advised AeroCare Holdings Inc. in its announced all-stock merger with MergeWorthRx Corp. According to the terms of the agreement, AeroCare will become a public company upon completion of the transaction and its existing stockholders will own 53% of the post-merger company. The deal is expected to close in the fourth quarter of 2014. Additional information can be found in the MergeWorthRx press release.
AeroCare, based in Orlando, Fla., is a provider of oxygen, respiratory, sleep and other chronic therapy services to patients in the home. The Company also provides sleep apnea devices. AeroCare serves more than 150,000 patients and generates annual revenue of approximately $150 million through a network of 175 locations across 20 U.S. states.
Miami, Fla.-based MergeWorthRx is a special purpose acquisition company formed on January 22, 2013 with the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses, with specific investment focus on the U.S. healthcare industry. MergeWorthRx’s common stock is traded on NASDAQ under the ticker symbol “MWRX.”
The Goodwin team advising AeroCare was led by partners Stuart Rosenthal and Jocelyn Arel.